Sarizotan

From Self-sufficiency
Jump to: navigation, search
Sarizotan
File:Sarizotan.png
Systematic (IUPAC) name
1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-([5-(4-fluorophenyl)pyridin-3-yl]methyl)methanamine
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 177975-08-5
ATC code none
PubChem CID 6918388
ChemSpider 2319847
Chemical data
Formula C22H21FN2O
Molar mass 348.413 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Sarizotan (EMD-128,130) is a selective 5-HT1A receptor agonist and D2 receptor antagonist,[1] which has antipsychotic effects,[2][3] and has also shown efficacy in reducing dyskinesias resulting from long-term anti-Parkinsonian treatment with levodopa.[4][5][6][7]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Antipsychotics (neuroleptics) (N05A)
Typical
Benzamides: Levosulpiride • Nemonapride • Sulpiride • Sultopride • Tiapride • Veralipride; Butyrophenones: Azaperone • Benperidol • Bromperidol • Droperidol • Fluanisone • Haloperidol • Lenperone • Moperone • Pipamperone • Spiperone • Timiperone • Trifluperidol; Diphenylbutylpiperidines: Clopimozide • Fluspirilene • Penfluridol • Pimozide; Phenothiazines: Acepromazine • Acetophenazine • Butaperazine • Carphenazine • Chloracizine • Chlorproethazine • Chlorpromazine • Cyamemazine • Dixyrazine • Fluacizine • Fluphenazine • Levomepromazine/Methotrimeprazine • Mesoridazine • Perazine • Periciazine • Perphenazine • Piperacetazine • Pipotiazine • Prochlorperazine • Promazine • Promethazine • Propiomazine • Sulforidazine • Thiethylperazine • Thiopropazate • Thioproperazine • Thioridazine • Trifluoperazine • Triflupromazine; Thioxanthenes: Chlorprothixene • Clopenthixol • Flupentixol • Thiothixene • Zuclopenthixol; Tricyclics: Amoxapine • Butaclamol • Fluotracen • Loxapine • Metitepine/Methiothepin • Octoclothiepin • Trimipramine; Others: Prothipendyl
Atypical
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)

Dopaminergics
Anticholinergics
Others


35px This drug article relating to the nervous system is a stub. You can help ssf by expanding it.
  1. ↑ Rabiner, EA; Gunn, RN; Wilkins, MR; Sedman, E; Grasby, PM (2002). "Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with 11CWAY-100635 and 11Craclopride". Journal of psychopharmacology (Oxford, England). 16 (3): 195–9. PMID 12236624.  edit
  2. ↑ Assié, M.; Ravailhe, V.; Faucillon, V.; Newman-Tancredi, A. (2005). "Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain". The Journal of pharmacology and experimental therapeutics. 315 (1): 265–272. doi:10.1124/jpet.105.087163. PMID 15987834.  edit
  3. ↑ Auclair, A.; Galinier, A.; Besnard, J.; Newman-Tancredi, A.; Depoortère, R. (2007). "Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats". Psychopharmacology. 193 (1): 45–54. doi:10.1007/s00213-007-0762-7. PMID 17393144.  edit
  4. ↑ Bibbiani, F; Oh, JD; Chase, TN (2001). "Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models". Neurology. 57 (10): 1829–34. PMID 11723272.  edit
  5. ↑ Bartoszyk, G.; Van Amsterdam, C.; Greiner, H.; Rautenberg, W.; Russ, H.; Seyfried, C. (2004). "Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile". Journal of neural transmission (Vienna, Austria : 1996). 111 (2): 113–126. doi:10.1007/s00702-003-0094-7. PMID 14767715.  edit
  6. ↑ Bara-Jimenez, W.; Bibbiani, F.; Morris, M.; Dimitrova, T.; Sherzai, A.; Mouradian, M.; Chase, T. (2005). "Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease". Movement disorders : official journal of the Movement Disorder Society. 20 (8): 932–936. doi:10.1002/mds.20370. PMID 15791634.  edit
  7. ↑ Grégoire, L.; Samadi, P.; Graham, J.; Bédard, P.; Bartoszyk, G.; Di Paolo, T. (2009). "Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys". Parkinsonism & related disorders. 15 (6): 445–452. doi:10.1016/j.parkreldis.2008.11.001. PMID 19196540.  edit
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Sarizotan&oldid=23908"